Vanguard Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$646K Hold
132,614
– – ﹤0.01% 2069
2026
Q2
$903K Buy
132,614
+42,140
+47% +$249K ﹤0.01% 1933
2026
Q1
$404K Buy
+90,474
New +$421K ﹤0.01% 2188

Other funds holding TSHA

Vanguard Asset Management's TSHA Position: Q3 2026 in Review

Vanguard Asset Management held its Taysha Gene Therapies (TSHA) position steady in Q3 2026 at 132,614 shares worth $646K. The position accounts for ﹤0.01% of the portfolio, ranked #2069.

Vanguard Asset Management first reported a position in TSHA in Q1 2026 and has held it in 3 quarters since. The position peaked at $903K in Q2 2026. 205 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Vanguard Asset Management held 132,614 shares of Taysha Gene Therapies worth $646K as of Q3 2026.
  • Vanguard Asset Management left its Taysha Gene Therapies share count unchanged in Q3 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #2069 holding.
  • Vanguard Asset Management first reported a position in Taysha Gene Therapies in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Asset Management's Taysha Gene Therapies position peaked at $903K in Q2 2026.
  • 205 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.